VYNE Therapeutics Inc.

VYNE

US92941V3087

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:23:32 2025-12-12 am EST			5-day change	1st Jan Change
0.3910 ^USD	-3.48%		+8.11%	-88.06%

Nov. 06	VYNE Therapeutics Q3 net loss narrows, strategic review ongoing	RE
Nov. 06	VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

VYNE Therapeutics Reports 'Positive' Phase 1a Results for VYN202 Inhibitor

Published on 12/23/2024 at 09:17 am EST - Modified on 12/23/2024 at 09:18 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about VYNE Therapeutics Inc.

Nov. 06	VYNE Therapeutics Q3 net loss narrows, strategic review ongoing	RE
Nov. 06	VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Aug. 14	VYNE Therapeutics Inc. Announces Resignation of Christine Borowski as Member of the Board and as A Member of the Nominating and Corporate Governance Committee	CI
Aug. 14	VYNE Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
Jul. 31	BTIG Research Downgrades VYNE Therapeutics to Neutral From Buy	MT
Jul. 30	Sector Update: Health Care Stocks Decline in Late Afternoon Trading	MT
Jul. 30	Sector Update: Health Care	MT
Jul. 30	Top Midday Decliners	MT
Jul. 30	VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo	CI
Jul. 30	Vyne Therapeutics' Phase 2b Trial of Repibresib Gel in Nonsegmental Vitiligo Misses Primary Endpoint	MT
Jul. 30	Vyne Therapeutics announces topline results from phase 2b trial with repibresib gel in nonsegmental vitiligo	RE
Jul. 02	VYNE Therapeutics Inc. Provides Program Update on Oral BET inhibitor VYN202	CI
May. 08	VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
Apr. 25	VYNE Says FDA Halted Psoriasis Drug Trial After Signs of Toxicity Found; Shares Down Pre-Bell	MT
Apr. 25	VYNE Therapeutics Provides Update on VYN202 Program	CI
Apr. 08	Artiva Biotherapeutics Names New Chief Medical Officer	MT
Mar. 17	Mindmed Appoints Matt Wiley as Chief Commercial Officer	CI
Mar. 06	VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI
Feb. 19	Vyne Therapeutics Initiates Phase 1B Trial Of Vyn202, A Novel Bd2-Selective Oral Bet Inhibitor, In Plaque Psoriasis	RE
Feb. 19	VYNE Therapeutics Inc. Initiates Phase 1B Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis	CI
Jan. 06	VYNE Therapeutics Completes Enrollment in Phase 2B Trial Evaluating Vyn201 for the Treatment of Nonsegmental Vitiligo	CI
Dec. 23	VYNE Therapeutics Reports 'Positive' Phase 1a Results for VYN202 Inhibitor	MT
Dec. 23	VYNE Therapeutics Inc. Therapeutics Reports Positive Top-Line Phase 1A MAD Data for VYN202, Its Novel BD2-Selective Bet Inhibitor	CI
Nov. 18	BTIG Initiates VYNE Therapeutics at Buy With $8 Price Target	MT
Nov. 07	Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q3 Revenue $121,000	MT

VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Employees

Sector

Biotechnology & Medical Research

Calendar

Feb. 25 - Q4 2025 Earnings Release (Projected)

More about the company